zalcitabine has been researched along with Body Weight in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Daniel, MJ; Donn, KH; Evans, GL; Hall, ST; Harker, AJ; Hussey, EK | 1 |
| Spector, SA | 1 |
| Fischl, MA; Follansbee, SE; Frame, PT; Henry, DH; Lalezari, JP; Lieberman, J; Lin, AH; Nauss-Karol, C; Olson, RM; Remick, SC; Salgo, MP; Soo, W | 1 |
| Brandi, G; Chiarantini, L; Fraternale, A; Magnani, M; Rossi, L; Schiavano, GF | 1 |
| Brawley, O; Broder, S; Cohen, RB; Nguyen, BY; Pluda, JM; Shay, LE; Venzon, DJ; Whitcup, SM; Wyvill, KM; Yarchoan, R | 1 |
| Collins, BJ; Dunnick, JK; Elwell, MR; Heath, JE; Irwin, RD; Lindamood, C; Prejean, D; Rao, GN; Sanders, VM | 1 |
| Buckley, LA; Collins, BJ; Foley, JF; Giles, HD; Heath, JE; May, RD; Rao, GN | 1 |
| Blanchard, S; Dankner, WM; Hodes, D; McIntosh, K; McNamara, J; Oleske, JM; Salgo, M; Spector, SA; Wara, DW | 1 |
| Black, PL; Evoniuk, G; Morse, DE; Ussery, MA | 1 |
| Boudinot, FD; Ibrahim, SS; Liotta, DC; Manning, C; McClure, HM; Schinazi, RF | 1 |
| Dunnick, JK; Giles, HD; Irwin, RD; Prejean, JD; Sutphin, ME; Thompson, MB | 1 |
| Dunnick, JK; Harris, M; Hoberman, AM; Lindström, P; Morrissey, RE | 1 |
1 review(s) available for zalcitabine and Body Weight
| Article | Year |
|---|---|
HIV therapy advances. Pediatric antiretroviral choices.
Topics: Body Weight; Clinical Trials as Topic; Didanosine; Female; Growth; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Pregnancy; Pregnancy Complications, Infectious; Treatment Failure; Zalcitabine; Zidovudine | 1994 |
3 trial(s) available for zalcitabine and Body Weight
| Article | Year |
|---|---|
Interspecies scaling and pharmacokinetic parameters of 3TC in humans.
Topics: Animals; Antiviral Agents; Body Weight; Cross-Over Studies; Dogs; HIV Seropositivity; Humans; Infusions, Intravenous; Lamivudine; Male; Rats; Reverse Transcriptase Inhibitors; Species Specificity; Zalcitabine | 1994 |
Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
Topics: Adult; Body Weight; CD4-Positive T-Lymphocytes; Female; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Leukocyte Count; Male; Regression Analysis; Severity of Illness Index; Survival Rate; Zalcitabine; Zidovudine | 1993 |
Comparative trial of two dosages of zalcitabine in zidovudine-experienced children with advanced human immunodeficiency virus disease. Pediatric AIDS Clinical Trials Group.
Topics: Adolescent; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Core Protein p24; HIV Infections; Humans; Infant; Male; Zalcitabine; Zidovudine | 1997 |
8 other study(ies) available for zalcitabine and Body Weight
| Article | Year |
|---|---|
Inhibition of murine retrovirus-induced immunodeficiency disease by dideoxycytidine and dideoxycytidine 5'-triphosphate.
Topics: Administration, Oral; Animals; Antiviral Agents; Body Weight; Deoxycytosine Nucleotides; Dideoxynucleotides; Disease Models, Animal; Drug Carriers; Erythrocytes; Female; Gene Products, gag; Immunoblotting; Immunoglobulin G; Immunoglobulin M; Immunohistochemistry; Lactates; Lymph Nodes; Lymphocytes; Macrophages; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Retroviridae; Spleen; Zalcitabine | 1993 |
A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; AIDS-Related Complex; Antigens, CD; Biomarkers; Body Weight; CD4 Antigens; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Core Protein p24; Humans; Male; Middle Aged; Pilot Projects; T-Lymphocyte Subsets; Time Factors; Zalcitabine; Zidovudine | 1993 |
Induction of thymic lymphoma in mice administered the dideoxynucleoside ddC.
Topics: Animals; Antiviral Agents; Atrophy; Body Weight; Female; Intubation, Gastrointestinal; Lymphoma; Male; Mice; Mice, Inbred Strains; Organ Size; Thymus Gland; Thymus Neoplasms; Zalcitabine | 1995 |
Carcinogenicity of 2',3'-dideoxycytidine in mice.
Topics: Anemia; Animals; Anti-HIV Agents; Atrophy; Body Weight; Carcinogenicity Tests; CD4-CD8 Ratio; Female; Lymphoma, T-Cell; Male; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Sex Factors; Species Specificity; Thymus Gland; Thymus Neoplasms; Time Factors; Tumor Suppressor Protein p53; Zalcitabine | 1996 |
Neuropathologies associated with dideoxycytosine: a preliminary assessment.
Topics: Acoustic Stimulation; Animals; Antiviral Agents; Body Weight; Dogs; Drinking Behavior; Feeding Behavior; Female; Haplorhini; Leukemia, Experimental; Male; Mice; Mice, Inbred BALB C; Motor Activity; Neurotoxins; Rabbits; Rats; Rats, Inbred Strains; Rauscher Virus; Reflex, Startle; Zalcitabine | 1992 |
Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys.
Topics: Administration, Oral; Animals; Antiviral Agents; Body Weight; Emtricitabine; Injections, Intravenous; Macaca mulatta; Male; Stereoisomerism; Tissue Distribution; Zalcitabine | 1992 |
Hematologic toxicity of AZT and ddC administered as single agents and in combination to rats and mice.
Topics: Animals; Blood Cell Count; Body Weight; Bone Marrow; Bone Marrow Cells; Eating; Female; Hematologic Diseases; Hemoglobins; Male; Mice; Mice, Inbred Strains; Rats; Rats, Inbred F344; Thrombocytopenia; Zalcitabine; Zidovudine | 1991 |
Developmental toxicity of orally administered 2',3'-dideoxycytidine in mice.
Topics: Animals; Body Weight; Dose-Response Relationship, Drug; Female; Fetus; Maternal-Fetal Exchange; Mice; Mice, Inbred C57BL; Pregnancy; Teratogens; Zalcitabine | 1990 |